ARCT vs JBIO

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Oct 23, 2026

ARCT

63.5
AI Score
VS
ARCT Wins

JBIO

41.4
AI Score

Investment Advisor Scores

ARCT

64score
Recommendation
BUY

JBIO

41score
Recommendation
HOLD

AI Analyst Insights

AI insights temporarily unavailable

Detailed Metrics Comparison

Metric ARCT JBIO Winner
Net Income -65.78M -96.13M ARCT
Operating Income -76.26M -102.36M ARCT
ROE -30.7% -21.9% JBIO
ROA -24.3% -20.4% JBIO
Total Assets 271.15M 472.11M JBIO
Cash 230.91M 107.25M ARCT
Current Ratio 6.64 14.93 JBIO
Free Cash Flow -74.50M -67.93M JBIO

Relative Price Performance (Last 90 Days)

ARCT 1M: -29.4% · 3M: +73.1% JBIO 1M: -1.0% · 3M: -26.9%

Current Technical Phase

ARCT

Neutral
Hold

Mixed signals - no dominant trend phase, RSI 36

RSI (14): 35.6 · Price: $9.97

JBIO

Markdown
Sell / avoid

Price below a falling SMA50 (slope -13.5%), weak momentum, RSI 45

RSI (14): 44.8 · Price: $14.58

Fundamentals Snapshot

Metric ARCT JBIO
Market Cap — —
Forward P/E -2.9 -5.6
Trailing P/E — —
Revenue (TTM) — —
Revenue Growth -0.9% 0.0%
Gross Margin -2.0% —
Operating Margin -8.6% 0.0%
EPS -3.33 -1.92
Dividend Yield — —

Frequently Asked Questions

Based on our detailed analysis, ARCT is currently the stronger investment candidate, winning 3 of the key financial metrics based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.